Immunogenicity and safety of the 9-valent HPV vaccine in men. (Q40767571)

23 September 2017

title

Immunogenicity and safety of the 9-valent HPV vaccine in men. (English)

1 reference

23 September 2017

1 reference

X Castellsagué

1

1 reference

23 September 2017

A R Giuliano

2

1 reference

23 September 2017

S Goldstone

3

1 reference

23 September 2017

A Guevara

4

1 reference

23 September 2017

O Mogensen

5

1 reference

23 September 2017

J M Palefsky

6

1 reference

23 September 2017

T Group

7

1 reference

23 September 2017

C Shields

8

1 reference

23 September 2017

K Liu

9

1 reference

23 September 2017

R Maansson

10

1 reference

23 September 2017

A Luxembourg

11

1 reference

23 September 2017

S S Kaplan

12

1 reference

23 September 2017

language of work or name

English

0 references

publication date

2 July 2015

1 reference

23 September 2017

1 reference

23 September 2017

volume

33

1 reference

23 September 2017

issue

48

1 reference

23 September 2017

page(s)

6892-6901

1 reference

The biology and life-cycle of human papillomaviruses.

23 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.06.088

Global burden of human papillomavirus and related diseases.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.06.088

Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.06.088

Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.06.088

Efficacy of a quadrivalent prophylactic human papillomavirus (types 6, 11, 16, and 18) L1 virus-like-particle vaccine against high-grade vulval and vaginal lesions: a combined analysis of three randomised clinical trials

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.06.088

Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.06.088

Early effect of the HPV vaccination programme on cervical abnormalities in Victoria, Australia: an ecological study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.06.088

Impact of human papillomavirus (HPV) vaccination on HPV 16/18-related prevalence in precancerous cervical lesions

7 January 2021

2 references

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.06.088

7 January 2021

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.06.088

inferred from DOI database lookup

7 January 2021

based on heuristic

Early impact of human papillomavirus vaccination on cervical neoplasia--nationwide follow-up of young Danish women

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.06.088

Effectiveness of quadrivalent human papillomavirus vaccine for the prevention of cervical abnormalities: case-control study nested within a population based screening programme in Australia.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.06.088

Fall in Human Papillomavirus Prevalence Following a National Vaccination Program

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.06.088

Vaccine-type human papillomavirus and evidence of herd protection after vaccine introduction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.06.088

Reduction in human papillomavirus (HPV) prevalence among young women following HPV vaccine introduction in the United States, National Health and Nutrition Examination Surveys, 2003-2010.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.06.088

The near disappearance of genital warts in young women 4 years after commencing a national human papillomavirus (HPV) vaccination programme

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.06.088

Evidence of human papillomavirus vaccine effectiveness in reducing genital warts: an analysis of California public family planning administrative claims data, 2007-2010

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.06.088

Incidence of genital warts in Sweden before and after quadrivalent human papillomavirus vaccine availability.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.06.088

Significant decrease in the incidence of genital warts in young Danish women after implementation of a national human papillomavirus vaccination program.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.06.088

HPV vaccine against anal HPV infection and anal intraepithelial neoplasia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.06.088

Efficacy of quadrivalent HPV vaccine against HPV Infection and disease in males

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.06.088

HPV vaccination in boys and men.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.06.088

Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.06.088

Potential impact of a nine-valent vaccine in human papillomavirus related cervical disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.06.088

A review of clinical trials of human papillomavirus prophylactic vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.06.088

Worldwide human papillomavirus genotype attribution in over 2000 cases of intraepithelial and invasive lesions of the vulva

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.06.088

Human papillomavirus DNA prevalence and type distribution in anal carcinomas worldwide.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.06.088

Large contribution of human papillomavirus in vaginal neoplastic lesions: a worldwide study in 597 samples

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.06.088

A 9-Valent HPV Vaccine against Infection and Intraepithelial Neoplasia in Women

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.06.088

Immunogenicity and Safety of a 9-Valent HPV Vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.06.088

Development of a human papillomavirus competitive luminex immunoassay for 9 HPV types

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.06.088

Development of neutralizing monoclonal antibodies for oncogenic human papillomavirus types 31, 33, 45, 52, and 58

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.06.088

Comparative analysis of two rates

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.06.088

Immunogenicity of the quadrivalent human papillomavirus (type 6/11/16/18) vaccine in males 16 to 26 years old

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.06.088

Classification of papillomaviruses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.06.088

Original antigenic sin responses to influenza viruses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.06.088

IL-10 Mediates Suppression of the CD8 T Cell IFN-γ Response to a Novel Viral Epitope in a Primed Host

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.06.088

Human papillomavirus vaccines--immune responses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.06.088

Concordance assessment between a multiplexed competitive Luminex immunoassay, a multiplexed IgG Luminex immunoassay, and a pseudovirion-based neutralization assay for detection of human papillomaviruse types 16 and 18.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.06.088

Comparison of the immunogenicity and reactogenicity of a prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in male and female adolescents and young adult women

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.06.088

Evaluation of the Long-Term Anti-Human Papillomavirus 6 (HPV6), 11, 16, and 18 Immune Responses Generated by the Quadrivalent HPV Vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.06.088

Safety and immunogenicity of a 9-valent HPV vaccine in females 12-26 years of age who previously received the quadrivalent HPV vaccine.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.06.088

Original antigenic sin in dengue

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.06.088

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/J.VACCINE.2015.06.088

1 reference

23 September 2017

1 reference